FDA.reportPublic FDA data

PMA P150025S014

Device
PD-L1 IHC 28-8 pharmDx
Applicant
Agilent Technologies, Inc.
PMA number
P150025
Supplement
S014
Product code
PLS
Decision date
2021-10-18
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Approval order statement
Approval to update the current approved urothelial carcinoma (UC) indication of PD-L1 IHC 28-8 pharmDx: to include enhanced disease-free survival and new clinical data from Bristol-Myers Squibb (BMS) clinical study CA209274 (CHECKMATE-274) in this existing indication.PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and urothelial carcinoma (UC) tissues using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of evaluable tumor cells exhibiting partial or complete membrane staining at any intensity.Companion Diagnostic IndicationTumor Indication PD-L1 ExpressionClinical Cutoff Intended UseNSCLC >= 1% tumor cell expression PD-L1 ICH 28-8 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with OPDIVO (nivolumab) in combination with YERVOY (ipilimumab).When used in accordance with approved therapeutic labeling:PD-L1 expression (>= 1% or >= 5% or >= 10% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC (nsNSCLC) may be associated with enhanced survival from OPDIVO.PD-L1 expression (>= 1% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in SCCHN may be associated with enhanced survival from OPDIVO.PD-L1 expression (>= 1% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in UC may be associated with enhanced response rate and enhanced disease-free survival from OPDIVO®.See the OPDIVO® and YERVOY® product labels for specific clinical circumstances guiding PD-L1 testing.

Current openFDA PMA Record#

Device
PD-L1 IHC 28-8 pharmDx
Applicant
Agilent Technologies, Inc.
PMA number
P150025
Supplement
S014
Product code
PLS
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Decision date
2021-10-18
Decision code
APPR
Date received
2021-07-12
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Approval order statement
Approval to update the current approved urothelial carcinoma (UC) indication of PD-L1 IHC 28-8 pharmDx: to include enhanced disease-free survival and new clinical data from Bristol-Myers Squibb (BMS) clinical study CA209274 (CHECKMATE-274) in this existing indication.PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and urothelial carcinoma (UC) tissues using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of evaluable tumor cells exhibiting partial or complete membrane staining at any intensity.Companion Diagnostic IndicationTumor Indication PD-L1 ExpressionClinical Cutoff Intended UseNSCLC >= 1% tumor cell expression PD-L1 ICH 28-8 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with OPDIVO (nivolumab) in combination with YERVOY (ipilimumab).When used in accordance with approved therapeutic labeling:PD-L1 expression (>= 1% or >= 5% or >= 10% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC (nsNSCLC) may be associated with enhanced survival from OPDIVO.PD-L1 expression (>= 1% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in SCCHN may be associated with enhanced survival from OPDIVO.PD-L1 expression (>= 1% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in UC may be associated with enhanced response rate and enhanced disease-free survival from OPDIVO®.See the OPDIVO® and YERVOY® product labels for specific clinical circumstances guiding PD-L1 testing.